Recombinant Human 5'-Nucleotidase/CD73 Fc Avi-tag, CF

Catalog #: AVI11377 Datasheet / COA / SDS

Fc Chimera

Catalog #	Availability	Size / Price	Qty
AVI11377-025

1 Image

All 5'-Nucleotidase/CD73 Proteins and Enzymes

Product Details

Supplemental Products

Reviews

Summary Product Datasheets Carrier Free Data Images Reconstitution Calculator Background Related Research Areas

Recombinant Human 5'-Nucleotidase/CD73 Fc Avi-tag, CF Summary

Product Specifications

Endotoxin Level

<1.000 EU per 1 µg of the protein by the LAL method.

Activity

Measured by its ability to hydrolyze the 5’-phosphate group from the substrate adenosine-5’-monophosphate (AMP). The orthophosphate product is measured by a Malachite Green Phosphate Detection Kit (Catalog # DY996).
The specific activity is >5500 pmol/min/μg, as measured under the described conditions.

Measured by its binding ability in a functional ELISA.
Biotinylated Recombinant Human 5'-Nucleotidase/CD73 Fc Chimera Avi-tag (Catalog # AVI11377) binds Human/Equine 5'-Nucleotidase/CD73 Antibody (Catalog # MAB5795) with an ED₅₀ of 3.00-30.0 ng/mL.

Accession #

AAH65937.1

N-terminal Sequence
Analysis

Trp27

Structure / Form

Biotinylated via Avi-tag

Predicted Molecular Mass

86 kDa

SDS-PAGE

88-98 kDa, under reducing conditions

Product Datasheets

AVI11377

Product Datasheet

COA

SDS

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

AVI11377

Formulation	Supplied as a 0.2 μm filtered solution in Tris, NaCl, CaCl₂ and Glycerol.
Shipping	The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage:	Store the unopened product at -70 °C. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Do not use past expiration date.

Scientific Data

Binding Activity

View Larger

Biotinylated Recombinant Human 5'-Nucleotidase/CD73 Fc Chimera Avi-tag Protein (Catalog # AVI11377) binds Human/Equine 5'-Nucleotidase/CD73 Antibody (MAB5795) with an ED₅₀ of 3.00-30.0 ng/mL.

Reconstitution Calculator

Background: 5'-Nucleotidase/CD73

CD73, known as ecto-5'-Nucleotidase, converts extracellular nucleoside 5' monophosphates to nucleosides, with AMP as its preferred substrate (1). CD73 is a zinc-dependent, homodimeric enzyme bound to the cell membrane through a glycosyl phosphatidylinositol (GPI) anchor. It is composed of an N-terminal domain containing metal binding sites linked via small hinge region to a C-terminal domain containing the substrate binding site and dimerization interface (2). It is expressed by most cell types (3) and is widely expressed in tumor cell lines as well as upregulated in cancerous tissues (4, 5). CD73 is a key enzyme responsible for a rate-limiting step in the generation of extracellular adenosine. Adenosine is a molecule that signals through activation of purinergic receptors and results in an immunosuppressive role in the tumor microenvironment (4, 6). CD73 has been implicated in many pathological processes including immunomodulation and inflammation (7,8) tumor growth and metastasis (9-13) making CD73 a potential drug target in cancer. Targeting CD73 inhibition has resulted in numerous reports of favorable antitumor effects (4, 5, 12). Consequently, therapeutic approaches have been tested using knockdown, gene silencing and anti-CD73 therapies (11, 14) as well as small molecule inhibitors (14, 15).

References

Zimmermann, H. et. al. (2012) Purinergic Signal. 8:437.
Knapp, K. et. al. (2012) Structure. 20:2161.
Resta, R. et. al. (1998) Immunol. Rev. 161:95.
Jin, D. et. al. (2010) Cancer Res. 70:2245.
Zhang, B. (2010) Cancer Res. 70:6407.
Picher, M. et. al. (2003) J. Biol. Chem. 278:13468.
Antonioli, L. et. al. (2012) Curr. Drug Targets 13:842.
Eltzchig, H.K. et. al. (2012) N. Engl. J. Med. 367:2322.
Bavaresco, L. et. al. (2008) Mol. Cell Biochem. 319:61.
Yegutkin, G.G. et. al. (2011) Eur. J. Immunol. 41:1231.
Stagg, J. et. al. (2012) Cancer Res. 72:2190.
Ghalamfarsa, G. et. al. (2019) Expert Opin. Ther. Targets. 23:127.
Gao, Z.W. et. al. (2014) Biomed. Res. Int. 2014:460654.
Young, A. et. al. (2014) Cancer Discov. 4:879.
McManus, J. et. al. (2018) SLAS Discov. 23:264.

Entrez Gene IDs

4907 (Human); 23959 (Mouse); 58813 (Rat); 102114976 (Cynomolgus Monkey)

Alternate Names

5' nucleotidase (CD73); 5'-NT; 5-NT; 5'-Nucleotidase; 5'-nucleotidase, ecto (CD73); CD73 antigen; CD73; E5NT; EC 3.1.3.5; ecto-5'-nucleotidase; eN; eNT; NT; NT55'-nucleotidase; NT5E; NTE; Purine 5-Prime-Nucleotidase